Merck & Co. Inc. managers escaped allegations that they hurt the pharmaceutical giant by misleading investors over traction ...

While HHS Secretary Kennedy frets over food dye in Froot Loops, his 2023 attack on Gardasil — a vaccine proven to prevent ...

One dose of a human papillomavirus (HPV) vaccine was noninferior to two doses in preventing infection, data from a randomized ...

Merck unveiled encouraging Phase 3 KEYNOTE-689 trial results for KEYTRUDA at the AACR 2025 Meeting, sparking investor ...

The firm reported revenues of $15.53 billion and adjusted earnings per share of $2.22, surpassing consensus predictions of ...

A new study seems to confirm that a single dose of the vaccine used to prevent HPV infection is just as effective as two — ...

Market volatility has led to compelling dividend opportunities, and Merck and Schlumberger offer great value at low PE ratios ...

Detailed price information for Summit Therapeu ADR (SMMT-Q) from The Globe and Mail including charting and trades.

Merck maintained its 2025 full-year revenue guidance of $64.1 billion to $65.6 billion, representing 1% to 3% growth excluding foreign exchange impacts. EPS guidance was adjusted to $8.82 to $8.97, ...

Merck & Co. said it expects to lose $200 million to already-announced tariffs in 2025 amid a roiling trade war between the US ...

The company’s stock fell as much as 2.8% after markets opened in New York Thursday. For the first quarter, Merck’s results beat estimates. First quarter sales were $15.5 billion, above the $15.3 ...

Merck said the expected tariff charge primarily reflects levies between the U.S. and China, but does not account for Trump’s ...